“Alpha Tau (NASDAQ: $DRTS is an exciting company with a lot of shots on goal” Read the full @SeekingAlpha article here: seekingalpha.com/article/491…

If the scumbags who short biotech every time there was good news knew how much more they could make by letting the market rip, they would be billionaires instead of fat, bloated, angry whales.

This is the diamond among rocks comment. Too many will get a dopamine fear hit and miss it. Codex went nuts over the past several months. They knew they had the ability and capacity and Claude didn’t. Every week, they were resetting limits and stealing users from Claude.

Fox Business said it right: ASCO 2026 is the Super Bowl of oncology and Alpha Tau is the rising star in the game that is becoming impossible to ignore.

$DRTS mentioned by @WassimLaroussi3 on the @BiotechTV weekly review. The stock that announced Complete Response in Recurring GBM last week, is heading into the ASCO week with momentum, where it is expected to announce Survival Data in Pancreatic Cancer. Stay tuned!

$DRTS with good early clinical trial results for glioblastoma and pancreatic cancer. Analysts have PT of $15 Currently $10.42 and up 108% YTD Further positive results in clinical trials would make a potential acquisition or revenue generating opportunity.

Ever heard of the "Abscopal Effect"? It’s when treating one cancer tumor triggers the immune system to destroy distant, untreated tumors elsewhere in the body. We don't know the exact mechanisms of it, but it's been observed in $DRTS trials. It was never a targeted endpoint, so a rather pleasant surprise. The concept is beyond exciting: A localized treatment, having a cascade systemic effect. Relevant: pmc.ncbi.nlm.nih.gov/article… Credit: /u/dizzy-strategy-4622 and /u/emotional-breath-838 Not Financial advice, not medical advice.

$DRTS is expected to share Pancreatic Cancer Survival Data for the first time at ASCO this month The presentation comes following 100% DCR (Disease Control Rate) in Pancreatic Cancer, and achieving Complete Response in Recurring GBM The stock is up and climbing!

The Seahawks don’t care who they play or where or when. It’s an attitude like I haven’t seen since the LOB. It’s hard to defeat a team with both talent and confidence.

Jake Bobo is just like you or me. Except he wakes up in the morning and puts on his Super Bowl ring.

Offseason hits different when you have zero regrets from the previous season and you love the new rookies.

Doubled my $DRTS and $SLS positions today $SLS got hit hard recently with no fundamental changes $DRTS has been stagnating despite massively improving fundamentals and a catalyst-packed quarter ahead. Easy add. Catalysts potentially this quarter alone: Completing Phase 3 cSCC Completing US PanC trial Japan commercialization updates Keytruda combination trial news Partnerships brewing New PanC data New GBM results I know many of my followers are into photonics and tech, but coming from a medical background, I can't resist to share my enthusiasm. Just yesterday $DRTS dropped TWO major announcements: one from the US, one from Europe both Pancreatic Cancer related. Catalysts potentially this quarter alone: Completing Phase 3 cSCC Completing US PanC trial Japan commercialization updates Keytruda combination trial news Partnerships brewing New PanC data New GBM results Next week: DDW Oral Presentation with brand new PanC data. Also brewing: a PanC trial being prepared in Japan 🇯🇵 The market hasn't priced this in. Yet.

JUST IN: Alpha Tau (NASDAQ: $DRTS) to advance Pancreatic Cancer trial in Japan. Following the marketing approval for their Alpha DaRT treatment in H&N Cancer, and the amazing results for Pancreatic Cancer in other countries, DRTS is set to start the trial via their Japanese partner Hekabio.

until i get TurboQuant, I'm not able to use Hermes to code what I really want... Claude Cowork but with local LLM ability if you dont want this, you never used it if you do want this and can code it, ill use it

My Hermes project: Hermes, you will work recursively to become as close to Claude Cowork as possible, leveraging free APIs as much as you can.

i have only been on the Hermes Agent X group a few minutes but ive already gotten enormous value from it. Discord would be great if i lived in Discord (never was a product more aptly named.) x.com/i/communities/20362891…

Tried DeerFlow and am running back to Hermes. Gotta love a lot of local llm AI power with a low RAM impact. @NousResearch

goodbye LM Studio hello oMLX LM Studio is great and ill be back one day but... i dont need LM Link since i have Hermes i have apple silicon and oMLX allows me to easily run Qwen3.5-27B models (LM studio wouldnt) or i can get insane speed on 9B models.